Evidence map›Paper›PMID 38686626›Full record

ArticleCancer medicine2024

Enhanced CTLA-4 blockade anti-tumor immunity with APG-157 combination in a murine head and neck cancer.

Daniel Sanghoon Shin, Saroj Basak, Mysore S Veena, Begoña Comin-Anduix, Arjun Bhattacharya, Tien S Dong, Albert Ko, Philip Han, Jonathan Jacobs, Neda A Moatamed and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Daniel Sanghoon ShinDepartment of Medicine, Division of Hematology-Oncology, VAGLAHS/David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California, USA.ORCID 0000-0002-3784-5336
Saroj BasakDepartment of Medicine, Division of Hematology-Oncology, VAGLAHS/David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California, USA.
Mysore S VeenaDepartment of Medicine, Division of Hematology-Oncology, VAGLAHS/David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California, USA.
Begoña Comin-AnduixDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Arjun BhattacharyaDepartment of Chemistry and Biochemistry and the Institute for Quantitative and Computational Biology, UCLA, Los Angeles, California, USA.
Tien S DongDivision of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Albert KoDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Philip HanDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Jonathan JacobsDivision of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Neda A MoatamedDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Luis Avila
Matteo PellegriniDepartment of Chemistry and Biochemistry and the Institute for Quantitative and Computational Biology, UCLA, Los Angeles, California, USA.
Marilene WangDepartment of Surgery, VAGLAHS and Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Eri S SrivatsanDepartment of Surgery, VAGLAHS/David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
University of California, Los Angeles · USQB3 · USEquilibrium Research · GBVA West Los Angeles Medical Center · US

Funding

Role of ATRX, a chromatin remodeler, in immunotherapy responseI01BX005588 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI SHIN, DANIEL SANGHOON · 2022 to 2025
–
Modulation of the Intestinal Microbiome in Obesity by a High Protein DietIK2CX001717 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI JACOBS, JONATHAN PATRICK · 2018 to 2023
–
BLRD VA I01 BX005588CSRD VA IK2 CX001717
6 · The paper itself

Abstract

backgroundA phase I clinical study for patients with locally advanced H&N cancer with a new class of botanical drug APG-157 provided hints of potential synergy with immunotherapy. We sought to evaluate the efficacy of the combination of APG-157 and immune checkpoint inhibitors.

methodsCCL23, UM-SCC1 (human), and SCCVII (HPV-), MEER (HPV+) (murine) H&N cancer cell lines were utilized for in vitro and in vivo studies. We measured tumor growth by treating the mice with APG-157, anti-PD-1, and anti-CTLA-4 antibody combinations (8 groups). The tumor microenvironments were assessed by multi-color flow cytometry, immunohistochemistry, and RNA-seq analysis. Fecal microbiome was analyzed by 16S rRNA sequence.

resultsAmong the eight treatment groups, APG-157 + anti-CTLA-4 demonstrated the best tumor growth suppression (p = 0.0065 compared to the control), followed by anti-PD-1 + anti-CTLA-4 treatment group (p = 0.48 compared to the control). Immunophenotype showed over 30% of CD8+ T cells in APG-157 + anti-CTLA-4 group compared to 4%-5% of CD8+ T cells for the control group. Differential gene expression analysis revealed that APG-157 + anti-CTLA-4 group showed an enriched set of genes for inflammatory response and apoptotic signaling pathways. The fecal microbiome analysis showed a substantial difference of lactobacillus genus among groups, highest for APG-157 + anti-CTLA-4 treatment group. We were unable to perform correlative studies for MEER model as there was tumor growth suppression with all treatment conditions, except for the untreated control group.

conclusionsThe results indicate that APG-157 and immune checkpoint inhibitor combination treatment could potentially lead to improved tumor control.

Indexed as

CTLA-4 AntigenHead and Neck NeoplasmsImmune Checkpoint InhibitorsTumor MicroenvironmentAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorDisease Models, AnimalFemaleHumansMiceProgrammed Cell Death 1 ReceptorCTLA-4 AntigenCtla4 protein, mouseImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorAPG‐157head and neck cancerimmune checkpoint inhibitorsmicrobiometumor microenvironment

Identifiers

PMID38686626
PMCPMC11058674
OpenAlexW4396534151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.